Suppression of DLBCL Progression by the E3 Ligase Trim35 Is Mediated by CLOCK Degradation and NK Cell Infiltration

The majority of diffuse large B-cell lymphoma (DLBCL) patients develop relapsed or refractory disease after standard ruxolitinib, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, which is partly related to a dysregulated tumor immune microenvironment. However, how th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Xiyan, Cao, Fuyang, Tang, Feiyu, Lu, Can, Yu, Qiaoyan, Feng, Songshan, Yang, Zhanghuan, Chen, Songming, He, Xiang, He, Jiang, Weng, Liang, Sun, Lunquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166485/
https://www.ncbi.nlm.nih.gov/pubmed/34124276
http://dx.doi.org/10.1155/2021/9995869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166485/
https://www.ncbi.nlm.nih.gov/pubmed/34124276
http://dx.doi.org/10.1155/2021/9995869

Ejemplares similares